On Thursday shares of Otonomy, Inc. (NASDAQ:OTIC) closed at $31.95. Company’s EPS growth for next 5 years is recorded as 22.30%. On May 12, Otonomy, Inc. (NASDAQ:OTIC) reported financial results for the quarter ended March 31, 2015. Cash, cash equivalents, and short-term investments totaled $223.6 million as of March 31, 2015, compared with $156.0 million as of December 31, 2014. This includes proceeds from the January 2015 follow-on public offering totaling approximately $80.0 million, net of underwriting discounts, commissions and offering-related transaction costs.
Galapagos NV (NASDAQ:GLPG) in last trading activity increased 20.10% to close at $50.50. Galapagos NV (NASDAQ:GLPG) a venture capital-backed biotech developing two drug candidates with AbbVie Inc., surpassed sweetened terms on Wednesday to rake in $275 million through its U.S. initial public offering and a concurrent private offering in Europe.
On last trading day Macquarie Infrastructure Company LLC (NYSE:MIC) increased 1.40% to close at $83.51. Its volatility for the week is 1.81% while volatility for the month is 1.73%. MIC’s sales growth for past 5 years was 13.70% and its EPS growth for past 5 years was 54.30%. Macquarie Infrastructure Company LLC (NYSE:MIC) monthly performance is -0.18%. On May 08, Macquarie Infrastructure Company (NYSE:MIC) announced that its International-Matex Tank Terminals (“IMTT”) business has received binding commitments from lenders for the refinancing of the business’ existing credit facilities. The refinancing is expected to close and fund on or about May 21 subject only to satisfaction of customary conditions precedent. New debt package comprises: $600 million senior notes; $509 million of tax exempt bonds; and $600 million undrawn revolving credit facility.
On Thursday shares of Sinovac Biotech Ltd. (NASDAQ:SVA) closed at $5.61. Company’s sales growth for last 5 years was 9.30% and EPS growth for next 5 years is recorded as 12.00%. Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, reported that its net loss attributable to common shareholders for the first quarter ended March 31, 2015 was $2.3 million or $0.04 per share, compared to net income of $4,000 or break even per share in the first quarter of 2014.
Pfizer Inc. (NYSE:PFE) in last trading activity increased 1.22% to close at $33.94. Company weekly performance is 1.07% while its quarterly performance stands at -1.86%. Pfizer Inc. (NYSE:PFE) is -3.68% away from its 52 week high. Pfizer Inc. (NYSE:PFE) announced that it has received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to its previously announced proposed acquisition of Hospira. The request for information from the FTC, often referred to as a “second request,” was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”).